Abstract
Since the introduction of cytology for cervical cancer screening more than 50 years ago, deaths from cervical cancer in the United States have declined by about 75% ( 1 ) . However, an estimated 3700 women will die from cervical cancer in the United States in 2005 ( 2 ) . Among the 55 million Pap smears performed in the United States annually, roughly 3 million show atypical cells of undetermined significance (ASCUS), a conundrum for pathologists, clinicians, and patients ( 3 ) .